Cargando…
Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?
We report a case of Guillain-Barré syndrome (GBS) following the first dose of Oxford/AstraZeneca COVID-19 vaccine with papilledema as atypical onset. As the COVID-19 vaccination campaign progresses worldwide, GBSs vaccine-related have been increasingly reported. After reviewing the available literat...
Autores principales: | Introna, Alessandro, Caputo, Francesca, Santoro, Carlo, Guerra, Tommaso, Ucci, Maria, Mezzapesa, Domenico Maria, Trojano, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360997/ https://www.ncbi.nlm.nih.gov/pubmed/34418708 http://dx.doi.org/10.1016/j.clineuro.2021.106887 |
Ejemplares similares
-
AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?
por: Oo, Wai M., et al.
Publicado: (2021) -
A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination
por: Bazrafshan, Hanieh, et al.
Publicado: (2022) -
Oxford–AstraZeneca COVID-19 vaccine efficacy
por: Knoll, Maria Deloria, et al.
Publicado: (2021) -
Lipschütz ulcers after AstraZeneca COVID-19 vaccination()
por: Bracho-Borro, Maria, et al.
Publicado: (2023) -
AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
Publicado: (2021)